Tag - LPTX

Developments

Leap Therapeutics DKN-01 gets FDA fast track designation for gastric and gastroesophageal junction cancer

The FDA granted Leap Therapeutics’ (NASDAQ:LPTX) DKN-01 fast track designation for gastric and gastroesophageal junction cancer. Specifically, the designation was granted for patients whose tumors express high Dickkopf...

September 24, 2020

Developments

Leap Therapeutics DKN-01 gets FDA orphan drug designation for gastric and gastroesophageal junction cancer

The FDA granted Leap Therapeutics’ (NASDAQ:LPTX) DKN-01 orphan drug designation for the treatment of gastric and gastroesophageal junction cancer. DKN-01 is a humanized monoclonal antibody that targets the Dickkopf-1...

June 12, 2020

Markets

HCW cuts Leap Therapeutics PT to $3.25 from $7.50

H.C. Wainwright lowered its price target for Leap Therapeutics (NASDAQ:LPTX) to $3.25 from $7.50 after the company decided to re-allocate resources and focus on advancing DKN-01, its anti-Dickkopf-1 antibody, while...

November 15, 2019

Tag - LPTX

Leap Therapeutics DKN-01 gets FDA fast track designation for gastric and gastroesophageal junction cancer

Leap Therapeutics DKN-01 gets FDA orphan drug designation for gastric and gastroesophageal junction cancer

HCW cuts Leap Therapeutics PT to $3.25 from $7.50

General

More